Wednesday, 31 August 2011
FIDDAMAN exclusive SARA CARLIN inquest details - thanks to our Canadian readers who wish to remain anonymous
CHIPMUNKA books so unwanted they give them away free
All too often we do business with nice people like you, and then go on
without giving it a second thought, as if we’d never done business together.
We would like to take a few minutes out of a busy day to personally thank
you for your business.
Thanks for trusting us with your business. We know you have a choice and
we’re glad you continue to choose us.
To say thank you, for the next 7 Days we will be offering 'Voices Beyond
The Border' as a FREE E-book download.
http://chipmunkapublishing.co.uk/shop/index.php?main_page=product_info&products_id=312
Tiny URL: http://goo.gl/xJds6
We would also like to remind you that you can download any or all of our 53
free e-books now from the link below!
http://chipmunkapublishing.co.uk/shop/index.php?main_page=specials
Tiny URL : http://goo.gl/4TyXp
These e-books will only be free until the end of September,
So download them now before you have to buy them in October!
All books are also available on Amazon Kindle and I-Books.
Pass this link
http://chipmunkapublishing.co.uk/shop/index.php?main_page=specials to your
colleagues, friends and to other people with mental illness so we can save
lives and make the world a place where people with mental illness are not
alone.
Connect with Chipmunka on the various social networking platforms below!
Twitter: http://twitter.com/#!/ChipmunkaBooks
Facebook:
http://www.facebook.com/pages/Chipmunkapublishing/166609206686368?sk=wall
Youtube: http://www.youtube.com/user/Chipmunkapublishing?ob=5
Linkedin: http://www.linkedin.com/company/chipmunkapublishing
Have a fantastic day from the Chipmunka team!
chipmunkapublishing
the mental health publisher
Unhappy Citalopram pill at work again - what about the alcohol, dosulepin & paracetamol ?
Unhappy Citalopram pill at work again but Leonie Fennell failed to mention the significant other drugs ..............always over eager to blame Lundbeck for Shane Clancy the love sick Irish murderer!
see reality here - http://www.thisischeshire.co.uk/news/2331736.gp_took_own_life/
A DEDICATED GP committed suicide after becoming unhappy with the long hours and business side of the job Warrington Coroners' Court heard today.
Dr Janet Wreglesworth, aged 43, of Hunts Lane, Stockton Heath, worked as a doctor in Runcorn from 1995 before moving to a surgery that she considered to be more traditional in Oldham.
�She couldn�t understand why other people couldn�t be as committed to the medical profession as she was. She had very high standards, she wanted to do the best she could do in any circumstances, which I think is admirable�
Husband, Brian Wreglesworth
The mum of two worked happily at the practice until one of the doctors and the practice manager left.
Her husband, Brian, said: "It was very difficult to get people to buy into the practice. The issue was that the interviews would take place after the evening surgery and she would often not be coming home until 10 or 11 at night.
"She didn't like running the business side of things and didn't like the interviewing. She wanted to be a doctor that's what she loved doing."
Mr Wreglesworth said that his wife loved treating people and that she got on well with her patients, who seemed to have great respect for her.
"She couldn't understand why other people couldn't be as committed to the medical profession as she was. She had very high standards, she wanted to do the best she could do in any circumstances, which I think is admirable," he added.
The pressure of work became too much for Dr Wreglesworth in November 2007 and she took time off work for stress. She was prescribed anti-depressants and was considered to be improving and fit enough to return to work when she was last seen by doctors on January 14.
The problems with the Oldham practice resulted in the partners deciding to sell the business to the PCT. Dr Wreglesworth had made plans with fellow GPs to become part of a salary partnership and do what she enjoyed best, looking after patients.
On the evening of February 18, she had discussed plans for a family holiday to France in August, before kissing her husband goodnight. She gave no indication of her intention to end her life.
In the morning, Dr Wreglesworth, who was off work with a chest infection, took her two sons, aged seven and 11, to the school Link Club before being discovered dead by Mr Wreglesworth on his return from work.
Pathologist Dr Mohammed Al-Jafari found that she died of alcohol intake, an overdose of anti-depressants, dosulepin, excessive intake of paracetamol and the prescribed anti-depressant, citlopram.
Coroner Dr Geoff Roberts, said: "She was not prescribed dosulepin when she died, she must have got them elsewhere. I have no doubt that she will have been aware that the combination would have been fatal, with the result that she killed herself with the combination. She committed suicide."
Speaking after the inquest, Mr Wreglesworth said: "I'm shocked. It never occurred to me. None of it makes any sense. We'd just booked a holiday. Everything was perfectly normal."
Monday, 29 August 2011
FIDDAMAN EMPOWERPLUS - child experiment age 7 -18 Bipolar !
Database analysis of children and adolescents
with Bipolar Disorder consuming a micronutrient
formula
Abstract
Background: Eleven previous reports have shown potential benefit of a 36-ingredient micronutrient formula (known as EMPowerplus) for the treatment of psychiatric symptoms. The current study asked whether children (7-18 years) with pediatric bipolar disorder (PBD) benefited from this same micronutrient formula; the impact of Attention-Deficit/Hyperactivity Disorder (ADHD) on their response was also evaluated.
Methods: Data were available from an existing database for 120 children whose parents reported a diagnosis of PBD; 79% were taking psychiatric medications that are used to treat mood disorders; 24% were also reported as ADHD. Using Last Observation Carried Forward (LOCF), data were analyzed from 3 to 6 months of micronutrient use.
Results: At LOCF, mean symptom severity of bipolar symptoms was 46% lower than baseline (effect size (ES) = 0.78)
(p < 0.001). In terms of responder status, 46% experienced >50% improvement at LOCF, with 38% still taking psychiatric medication (52% drop from baseline) but at much lower levels (74% reduction in number of medications being used from baseline). The results were similar for those with both ADHD and PBD: a 43% decline in PBD
symptoms (ES = 0.72) and 40% in ADHD symptoms (ES = 0.62). An alternative sample of children with just ADHD symptoms (n = 41) showed a 47% reduction in symptoms from baseline to LOCF (ES = 1.04). The duration of reductions in symptom severity suggests that benefits were not attributable to placebo/expectancy effects.
Similar findings were found for younger and older children and for both sexes.
Conclusions: The data are limited by the open label nature of the study, the lack of a control group, and the inherent self-selection bias. While these data cannot establish efficacy, the results are consistent with a growing body of research suggesting that micronutrients appear to have therapeutic benefit for children with PBD with or without ADHD in the absence of significant side effects and may allow for a reduction in psychiatric medications while improving symptoms. The consistent reporting of positive changes across multiple sites and countries are substantial enough to warrant a call for randomized clinical trials using micronutrients.
Background
The diagnosis of pediatric bipolar disorder (PBD) is one
of the most controversial in modern child psychiatry [1].
Disagreement exists on how to define it, at what age to
identify it, and how it matches with the more traditional
diagnosis of bipolar disorder in adulthood (see [2] for an
extensive review). However, regardless of how it is conceptualized
and whether changes in criteria have been
validated or supported by research, a consequence ofthe loosening of the Diagnostic and Statistical Manual’s
(DSM) definition [3] is that thousands of children and
young people have now been diagnosed with PBD and
prescribed psychiatric medications that have limited
empirical support and that often carry worrisome
adverse effects. The changes in the definition of PBD
have raised substantial debate [4]. The current DSM-V
task group is attempting to address the surge in diagnoses
of PBD with the introduction of a new category,
Temper Dysregulation Disorder with Dysphoria, which
is also controversial [5].
* Correspondence: julia.rucklidge@canterbury.ac.nz
† Contributed equally
CCHR Birmingham - down at heel private house - 30 Maxwell Avenue Birmingham - Chris Wrapson
http://www.trade-birmingham.co.uk/company/Citizens+Commission+On+Human+Rights++Birmingham/364376
Media Relations Officer
Citizens Commission on Human Rights Birmingham
30 Maxwell Avenue
Handsworth Wood
Birmingham
B20 3TT
ch...@cchr.org.uk or birming...@cchr.org.uk
07793 285 784 or 0845 260 2247
http://www.rightmove.co.uk/house-prices/detail.html?outcode=B20&incode=&streetName=Maxwell+Avenue&locality=Birmingham&country=england&buildType=1&propertyType=0&yearSelection=20&columnToSort=DEED_DATE&sortOrder=ascending&summaryIndex=100
Chris Wrapson (Volunteer)
Citizens Commission on Human Rights Birmingham
30 Maxwell Avenue
Handsworth Wood
Birmingham
B20 3TT
ch...@cchr.org.uk or birming...@cchr.org.uk
07793 285 784 or 0845 260 2247
HOUSE PRICES in Maxwell Avenue, Birmingham, B20 (England & Wales)
http://www.rightmove.co.uk/house-prices/detail.html?outcode=B20&incode=&streetName=Maxwell+Avenue&locality=Birmingham&country=england&buildType=1&propertyType=0&yearSelection=20&columnToSort=DEED_DATE&sortOrder=ascending&summaryIndex=100
Sunday, 28 August 2011
Rapper Chill E.B at Church of Scientology Gala .... need we say more?
+Kelly,+Chill+E.B.,+Elena+Roggero,+Michele+Henderson,+Jesse+Stevenson.jpeg)
(From left to right) Kelly, Chill E.B., Elena Roggero, Michele Henderson, Jesse Stevenson
CCHR: Industry of Cheese - anonymoustoronto
When talking about the Citizens Commission for Human Rights it is nearly impossible to separate them from the Church of Scientology. Regardless of what claims this group may make, the tactics of the former mirror those of the latter.
L Ron Hubbard was a paranoid schizophrenic. This can be seen throughout his writings, which would later become the scriptures of the Church of Scientology. CCHR, whether they claim to be a separate entity or not, also embraces these twisted ideals.
While watching "Psychiatry: Industry of death" by the CCHR the fears of the founder of the cult could be seen reflected within the claims of this propaganda film. They present it as if were a legitimate documentary, however many of the facts have been changed, exaggerated, doctored, and in same cases invented.
It's time to challenge these claims, and display the exaggerated conspiracy theory at its core.. Which have been passed down by the beliefs held within the Church of Scientology through the words of L Ron Hubbard.
Each of their claims will be dealt with one at a time, in order. At the same time each of their paranoid conspiracy theories will be displayed as what they are, for the world to judge.
This is, of course, an attempt to set the mood. I admit it's a bold opening, and scary voice-over guy does a great job sounding official as well as ominous. However this is clearly part of the conspiracy theory at it's core. Psychiatry is a medical industry composed predominantly of small practices. There are those who work in hospitals, clinics, and government agencies.
It's not some vast evil corporation. There's no real hierarchy to it, however there are experts at the top of this field as with any other. Just like in the medical profession, most got into the field to help others, some joined for the money, and a few to satisfy their egos.
The prescription drug companies advertise everywhere, but what company doesn't? This is a topic which will be dealt with more later in the series. However, at this juncture it seems prudent to point out that companies offering promotions to advocate their product over that of another company is not a reflection upon the field of psychiatry.
Psychiatrists do not hypnotize patients.. That's hypnotherapy not psychology or psychiatry. L Ron Hubbard in the scriptures of scientology insists otherwise, in numerous display of his paranoid delusional states during which he wrote.
Then again he also insists any pain drugs a person takes induces a form of hypnosis - this includes drugs like aspirin and ibuprofen, not just heavy narcotics.
Unless you live within a psychiatric ward, psychiatry is clearly not represented in every aspect of your life.. even if you ARE a psychiatrist or psychologist. However I should note.. if you happen to be paranoid, delusional, and obsessed with psychiatry this could certainly seem to be the case.. However it would be just as real as aliens reading peoples brain-waves unless you wear a tinfoil hat.
Now, for their next claim.. And an examination of their statistical manipulation, as well as poor math skills.
But before we begin, it is worth mentioning that those within the Church of Scientology are well known for misrepresenting numerical statistics. They claim that there are well over 8 million Scientologists. However, under oath, in a court of law, one of their representatives grudgingly admitted that the calculated 8 million included every person who ever took a course, living or dead, since they were founded. This includes those who take their WISE business courses, Applied Scholastic courses, anyone who was ever at Narconon even if they were part of the roughly 85% which wash out of the program.
scientology cchr psychiatry anonymous industry death debunk review cult xenu hubbard mental mealth depression ADHD dianetics reality history abuse american founding father Skinner Box Urban Legend behavioral science hitler nazi eugenics darwin galton museum conspiracy theory evolution cos propoganda psyche deception fraud warped racism politics drugs ECT Labotomy Shock Therapy depression Siberia USA ward commitment involuntary manipulation DSM prove chemical imbalance proof tom cruise
CCHR Toronto - seedy low rent above a printer shop - low rent like FIDDAMAN
Citizens Commission on Human Rights National Office
www.cchr.org/locations/cchr-toronto.html - CachedYou +1'd this publicly. Undo
27 Carlton Street, Suite 304 Toronto, Ontario M5B 1L2: Phone: 416-971-8555: Fax: Email: officemanager@on.aibn.com. View/Get Directions >>.
Saturday, 27 August 2011
Friday, 26 August 2011
TrueHope EMpowerplus - off the shelf pig nutrients - FIDDAMAN counterpoint blog
A. The development of EMpowerplus
[12] As an animal nutritionist, Mr. Hardy discovered that feeding certain nutrients to pigs helped alleviate their ear and tail biting syndrome. Mr. Hardy observed that certain behaviors in humans such as hyper-irritability as well as symptoms related to bipolar disorder are similar to what he observed in pigs and speculated that if people were given certain nutrients, their symptoms could also be alleviated.
[13] In 1995, Mr. Anthony Stephan, also a co-founder of TrueHope, sought Mr. Hardy’s advice about treating the poor mental health of his children: his daughter Autumn was delusional and suicidal, and his son, Joseph suffered from bursts of uncontrollable rage. Given Mr. Hardy’s positive experience with treating similar conduct in pigs as a nutrient deficiency, they placed
[14] In 1996, the positive experience with using nutrients to help people deal with their mental problems led Mr. Hardy and Mr. Stephan to develop the Quad Program, a treatment protocol of supplement vitamins and mineral nutrients. In 1996, Mr. Hardy and Mr. Stephan incorporated the Synergy Group of Canada Inc. (Synergy) to promote research into the Quad Program and observe its results. A Quad Program study at the University of Lethbridge and the University of Calgary revealed that due to inconsistency in the mineral supplements, people on the protocol faltered. Mr. Hardy and Mr. Stephan sought to improve the Quad Program and did so by developing a single and consistent product, being EMpowerplus.
FIDDAMAN book - Pig Pills, Inc. - The Anatomy of an Academic and Alternative Health Fraud
Their pitch was based on the absurd notion that young piglets on their way to becoming ham for your dinner table could be cured of a condition that is know as Ear and Tail Biting Syndrome. They claimed that pigs of course could be healed by just throwing them a haphazard mixture of vitamins, minerals, and herbs - the pig pills. Yes, pig pills! Then in an amazing leap of faith, these two fellows from rural Alberta, Canada, with connections to nutraceutical conglomerates in Utah, came up with the idea that their pig pill formula could help wipe out the scourges of otherwise incurable mental illness in humans.
Pig Pills, Inc. is based on over two-years of research into The Synergy Group of Canada, their product E.M Power +, Dr. Bonnie Kaplan PhD, Department of Pediatrics, University of Calgary, and:
How the Alberta government spent close to $3/4 million funding research based on this “cure”.
How Health Canada spent close to a year attempting to make a senior research psychologist from the Alberta Children's Hospital and the University of Calgary comply with the Food & Drugs Act and stop this dubious research.
How the Alberta government funded research on American children in spite of explicit refusal of permission to do so.
How Canada Customs issued orders to seize the pills at the border, and yet the research continued and sales to individuals continue to this day.
How products made by a company that had been warned by both the U.S. FTC and the FDA for making false health claims for their products, were approved for research with children at the University of Calgary.
How a respected Harvard affiliated psychiatrist participated.
How yet another pediatric psychiatrist at the University of Utah conducted research studies that his institution had not approved.
How major media outlets bought the "pig pill cure" hook line and sinker, and fueled the story around the world.
How the Canadian government has been unable to stop the sale of these pig pills, from June 2000, when the first complaint was received.
The biggest scandal of all, however, is the number of innocent people who have been, or could have been harmed because they followed the advice of untrained, lay people who advised them to either take their special "pig pills", or in many cases, stop their psychiatric medications altogether. The issue here is not the fact that people just wasted their money, some have had their hopes for good health shattered once again.
And readers will learn something amazing: if these folks conducted objectionable research on pigs, they could have faced staggering fines and penalties. Pigs - animals - used in research are protected by laws: humans, it would seem, aren't so lucky.
The Pig Pill, Inc. team:
Terry Polevoy, MD - Kitchener, Ontario physician and founder of healthwatcher.net
Ron Reinhold - Calgary, Alberta, Rainbow Investigations, and former Health Canada investigator
Marvin Ross - Hamilton, Ontario, Bridgeross Communications, freelance medical journalist and author
http://www.pigpills.com/
--------------------------------------------------------------------------------
Pig Pills, Inc.
Table of Contents
INTRODUCTION
CHAPTER 1 - CARDSTON, ALBERTA - THE DISCOVERY
CHAPTER 2 - PSYCHO PIGS
CHAPTER 3 - EARLY RESEARCH
CHAPTER 4 - BAIT AND SWITCH
CHAPTER 5 - RESEARCH AS MARKETING
CHAPTER 6 - SALES STRATEGIES & SPAM A LA CARTE
CHAPTER 7 - BONE PICKING @ THE U. OF CALGARY
CHAPTER 8 - RESEARCH ETHICS?
CHAPTER 9 - UNIVERSITY & RESEARCHERS AS SHILLS
CHAPTER 10 - PIGGING OUT
CHAPTER 11 - MILKING THE MEDIA
CHAPTER 12 - IT’S NOT THE LAW
CHAPTER 13 - SHOW ME THE MONEY
CHAPTER 14 - CORPORATE CHAMELEONS
APPENDIX 1 - ALBERTA & CALGARY COVER-UP
APPENDIX 2 - BARNYARD BULLIES
APPENDIX 3 - BONNIE KAPLAN ON SHRINK RAP
APPENDIX 4 - TRANSCRIPT OF A SALES PRESENTATION
APPENDIX 5 - FORMULAS COMPARED
APPENDIX 6 - SSO LETTER TO HEALTH CANADA
APPENDIX 7 - REVIS & BUTTHEADS
APPENDIX 8 - SYNERGY SPIN
APPENDIX 9 - CTV TRANSCRIPTS - AVIS FAVARO
ABOUT THE AUTHORS
BIBLIOGRAPHY - ON THE PIG PILL TRAIL
FIDDAMAN - TrueHope Empowerplus - We've made a blind girl see again!!!!!
We've made a blind girl see again!!!!!
Truehope's Empowerplus and other miracles
This report is from someone who attended a meeting hosted in Ohio by John Keim. They recorded their observations and opinion. I would judge them to be fair comments about the presenters and the products discussed. It is our job to report what others have to say in an objective manner. You be the judge if you believe this report or not.
David Hardy and Anthony Stephan presentation hosted by John Keim - September 16, 2009. Highlights
Subject: How to get off medications and experience good health by using Truehope products
Attendance: 150 people from Canada, Ohio, Pennsylvania, Kentucky, and Virginia.
Presenters: John Keim who organized the meeting in Shiloh, Anthony Stephan and David Hardy who founded Truehope in Alberta, Canada.
Testimonials were numerous, including the usual stories from Tony about his wife's suicide just two weeks after she went on Prozac. Both Tony and Dave tended to bring in the name of God whenever they felt it necessary. My guess is that the room was full of Amish or Mennonites that needed to hear it in order to lend evangelical credibility to their spiel.
The testimonials were liberally spread around with miraculous claims about a six year old children who was cured of blindness, to an older woman who was saved from hospitalization because her husband forced her to take the nutrients they were promoting.
Then there were the very unsubstantiated claims made by researchers done in five universities, including Ohio State University. No mention was made about the research studies that have been halted over the years by regulators in two countries.
It would appear that "everyone" needs to be supplemented with their stuff. Unsubstantiated claims were made that their product showed a huge difference when compared to placebo.
Once again the 150 people in the audience heard that this product can grow back brain cells, and because the Creator is a lot smarter than scientists, 90% of poor health would disappear if only people took supplements. I assume that meant THEIR supplements.
Does it help everyone? YES IT WILL....”It's a God given answer!”
Not only that – it's a scientific fact that 50 genetic illnesses can be cured with this program. The drug companies don't want you to know that this stuff works.
The cost of one bottle of 225 pills is $74.95 and was quoted in U.S. Dollars. And by the way you have to take 15 pills a day. It's not about the money, it's about helping people and just in case you didn't know, you have to take it for the rest of you life.
Anthony Stephan and David Hardy target Old Order Amish and Mennonites even though they are Mormon. Who is responsible for this?
FIDDAMAN True Hope - bi-ploar same as pig with ear-and-tail-biting syndrome
Stephan met David Hardy, a man educated in biological sciences who had spent twenty years as an animal feed formulator, after leaving his career as a high school biology teacher. While discussing carpeting for a church basement, Stephan broke down and poured out his heart to Hardy. Hardy listened carefully and then said an odd thing. He said that the bipolar behaviour of Stephan’s son, Joe, sounded to him like a pig with ear-and-tail-biting syndrome.
The story of Truehope began with one father’s desperate desire to save his children. Anthony Stephan’s wife, Debora, had bipolar disorder and had committed suicide in January of 1994. Debbie’s father had done the same sixteen years earlier. Now, a year later, two of Stephan’s children had also been diagnosed with bipolar disorder I, the most severe form of the illness. Both had been given a variety of heavy psychotropic medications, but both were getting worse and worse. Stephan could see that it was only a matter of time before he’d lose another loved one to the grip of bipolar affective disorder.
a father’s anguish
For a year after his wife’s death, Stephan searched the medical journals, read books and poured over everything he could find that might save his children, Autumn and Joe. When a specialist told him to give up and accept his children’s fate – that both would likely be ill, medicated, hospitalized and possibly, given the history, to die young – Stephan started a new kind of search. He believed that if there was an answer in the world that could save his kids, God knew it. He prayed ceaselessly, hoping that God would hear his cries and have mercy on his broken family.
a prayer is answered
the nutritional approach
Using Hardy’s extensive knowledge of pig feed supplementation, the two men formulated a human version of the regimen, using human grade supplements. Stephan’s children, Autumn and Joe, responded to the formula and were able to discontinue their medications. As they recovered and began to resume healthy lives, word spread through their communities. Stephan and Hardy were happy to share their regimen and soon there were hundreds of people trying this early version of what is now EMPowerplus.
the success stories increase
Reports of success continued to pour in and Stephan knew that there was more to be done to bring this odd discovery to the world. He convinced Hardy to leave his work with animal feed and together, in 1996, they formed a company to refine and produce their formula, which consisted, at the time, of a combination of various micronutrient treatments taken individually. The pair also sought to bring their results to the attention of scientists who they hoped would research their unorthodox approach. They realized that they had perhaps stumbled on a clue that would lead to a new understanding of what causes mental illnesses – and how to treat them.
scientists take notice
They systematically gathered information and data from new micronutrient treatment users and presented it to Dr. Bryan Kolb, a world-renowned neuropsychologist at the University of Lethbridge in southern Alberta. Intrigued, Dr. Kolb sent them to see Dr. Bonnie Kaplan, a behavioural research scientist at the University of Calgary, also in southern Alberta. Although initially skeptical, Dr. Kaplan agreed to try the micronutrient treatment in a preliminary trial. In order to facilitate the research, Stephan and Hardy put all the necessary ingredients into one capsule that could be administered easily. They found a manufacturer who would produce the product to their exact specifications and called their product EMPowerplus.
research begins
Once the all-in-one micronutrient treatment was available, Kaplan, together with her colleagues, put together preliminary open trials that showed significant promise as a treatment for mental illness, confirming the need for further research and grabbing the attention of researchers and specialists all across North America.
large studies underway
With the availability and legitimacy of use established, Dr. Kaplan and her colleagues were given permission by Health Canada to conduct a large double blind placebo study at the University of Calgary. This study is nearing completion, while other studies are also underway in Canada and the US. All at Truehope look forward with great excitement to the results of this and other research.
hope for the future
Truehope’s focus is to work to make sure that the EMPowerplus option is available to all who suffer with mental illness. It is our hope that as scientists play their part and as governments consider the welfare of all of their citizens, natural therapies like EMPowerplus will be made available through standard medical systems.
reflections of faith and hope
Anthony Stephan, in reflecting on the marvelous recovery of his children, said; "Truly God has answered my pleadings and intense prayers with a great blessing." Thousands of participants have borne that same witness and acknowledged the hand of God in bringing restoration to their life or that of a loved one. Hence, we have named this web site “TRUEHOPE” because we believe that true hope can only be found in the healing sustenance that God has provided for us. No man or company or science can ever replicate or replace that which our Creator has provided for us. In seeking to treat the symptom, we have all ignored the Source.
the stephan family in 1989
Thursday, 25 August 2011
CCHR Canada Annual Gala speaker - True Hope Empowerplus nutritional support - Anthony Stephan president and co-founder
Anthony Stephan, back AGAIN by popular demand from last year's gala, Mr. Stephan is the president and co-founder of True Hope nutritional support. If you've heard him before, come and show we still stand behind him and learn what he has been up to in the past year, if you haven't heard him speak before, then just ask someone who has, his story is not to be missed
FIDDAMAN - 2011 winner of the CCHR International Thomas Szasz Human Rights award. ....HaHaHaHaHaHa
Flying in from the UK is Bob Fiddaman - "The one man wrecking crew" Author, Human Rights Activist, and one of the biggest thorns in the side of Glaxo...SmithKline (the makers of Paxil) and 2011 winner of the CCHR International Thomas Szasz Human Rights award.
FIDDAMAN Trip - CCHR Canada Annual Gala Dinner and Briefing 2011
CCHR Canada Annual Gala Dinner and Briefing 2011
Share · Public event.Time 27 August · 18:00 - 21:00
http://en-gb.connect.facebook.com/event.php?eid=200236383363722&ref=nf
--------------------------------------------------------------------------------
Location Toronto, ON
--------------------------------------------------------------------------------
Created by: CCHR Canada
--------------------------------------------------------------------------------
More info The 2011 CCHR Canada's annual gala dinner and briefing is soon approaching! Come and enjoy a gourmet dinner and hear about what we have accomplished in the last year, and what we have planned for the next year.
This year we are proud to once again have two world-class guest speakers:
Flying in from the UK is Bob Fiddaman - "The one man wrecking crew" Author, Human Rights Activist, and one of the biggest thorns in the side of Glaxo...SmithKline (the makers of Paxil) and 2011 winner of the CCHR International Thomas Szasz Human Rights award.
Anthony Stephan, back AGAIN by popular demand from last year's gala, Mr. Stephan is the president and co-founder of True Hope nutritional support. If you've heard him before, come and show we still stand behind him and learn what he has been up to in the past year, if you haven't heard him speak before, then just ask someone who has, his story is not to be missed.
Tickets $125 per person.
To purchase your ticket call 416-971-8555 or email:
Lori Bryenton lori@cchrcanada.org or
Benjamin Middleton execdir@cchrcanada.org
SEROXAT user GROUP .co.uk - for USERS having difficulty getting off the drug
for USERS having difficulty getting off the drug .....so said group co moderator Derek Scott
Wednesday, 24 August 2011
~ Too Late For Prayin`~ GORDON LIGHTFOOT
It was only yesterday
When I heard the teacher say
Patiently, one and two make three
We were children, you and me
Let us pray for the ones they call
The children of today
Nothin' left but promises
Nothin' much is certain
All we see is want and need across the board, why thank you lord
We're livin' in the glory of your care
Skies of blue have all turned brown
To the sound of sighin'
Lord abide, let us stem the tide
Of broken dreams
Sometimes you seem to tell us
It's too late for prayin'
See the ocean wild and blue
Think of all that's in her
She will not surrender to the likes of us, but then she must
They tell us, wise men tell us, it's too late
For each child with eyes that smile
There'll be ten more cryin'
Lord abide, let us stem the time
Of helplessness
But then I guess we're livin'
Is it too late for tryin'?
Nothin' here but grains of sand
Nothin' much worth savin'
Guess we've all got problems of our own to bear, and still we share
Tomorrow could get better than today
To the ones who've loved in vain
Will ya be beholden
Lord abide, let us stem the tide
Of broken dreams
Sometimes ya seem to tell us
It's too late for prayin'
[ Lyrics from: http://www.lyricsfreak.com/g/gordon+lightfoot/too+late+for+prayin_20061681.html ]
Send "Too Late For Prayin'" Ringtone to your Cell Contact Us / Privacy Policy / ToS / LyricsFreak © 2010
FIDDAMAN latest trip T -1 .....will it be back to the past and AMSTERDAM PROSTITUTES ?
see
will Bob take the 4 door DeLorean?
one thing for sure is that once he's had a skinfull of booze & some blow .....the gates will not open
read all here - http://ssocialactivism.blogspot.com/2011/05/bob-fiddaman-bitch-told-me-i-talked-too.html
Tuesday, 23 August 2011
Pat McGorry's clinical trial - just like DeLorean Sedan it never happened
DMC Sedan
These extremely rare sketches were made by John DeLorean in November of 1979. They show early sketches of what the future DeLorean sedan may have been comprised of. In the first sketch, there appears to be the possibility that the seats may be reversed in the back so that the passengers sit facing the rear of the car, a most uncoventional method of design unless building a limo. What appears to be even more unconventional is the positioning of two flat four cylinder engines, one inf the front and one in the rear of the car. The second sketch shows a more conventional looking DeLorean sedan with many similar qualities to the sports car. The luggage and fuel tank would be up front, with the engine placed either mid transaxle or in the rear of the car. John was already foreseeing a turbo engine in the works, and was planning on carrying over many of the features from the sports car to the sedan.
Just like Bob Fiddaman it was a work of pure fantasy
Monday, 22 August 2011
LUNDBECK es citalopram the most prescribed branded antidepressant in the world - now
Launch of Lexapro commenced in Japan
* Clinical phase III studies in Japan have confirmed the positive efficacy and
tolerability profile of Lexapro(®)
* Lexapro(®) in Japan will contribute to Lundbeck's financial performance from
2012
H. Lundbeck A/S today announced that its partners Mochida Pharmaceutical Co.,
Ltd. (Mochida) and Mitsubishi Tanabe Pharma Corporation (MTPC) have launched
Lexapro(®) 10mg (escitalopram) in Japan, for which Mochida obtained the
marketing approval following the NHI (National Health Insurance) Drug Price
listing.
"It is a milestone in our global expansion strategy that Lexapro(®) is now
available in Japan following a fast regulatory process," says Lundbeck Senior
Vice President Ole Chrintz, International Markets. He continues: "We are pleased
that Lexapro(®) will now also contribute to improving quality of life for
patients in Japan diagnosed with depression."
Lexapro(®) has been very well-received by the patients and doctors for the
treatment of depression in many countries, and is currently the most prescribed
branded anti-depressant in the World.
Mochida and MTPC estimate sales of Lexapro(®) amounting to JPY 3 billion (DKK
~0.2 billion) for the first year following the launch and JPY 33.8 billion (DKK
~2.3 billion) in its peak year 6 years later.
For reference:
Brand Name: Lexapro(®) 10mg
Ingredients and Contents: 12.77mg escitalopram oxalate per tablet (10mg
escitalopram per tablet)
Indication: Depression and depressive symptoms
Dosage and Administration: Usually, to adults, 10mg of escitalopram is orally
administered once daily after meal in the evening. The dosage may be adjusted
according to the patient's age and symptoms; however, the daily dose should not
be increased over 20mg.
Package: 28,100,140,500 tablets (PTP), 500 tablets (Bottle)
NHI Drug Price: JPY 212.00 per tablet
Date of Approval: April 22, 2011
* Lexapro(®) - the most prescribed branded antidepressant in the world - now
also available to Japanese patients
* Clinical phase III studies in Japan have confirmed the positive efficacy and
tolerability profile of Lexapro(®)
* Lexapro(®) in Japan will contribute to Lundbeck's financial performance from
2012
H. Lundbeck A/S today announced that its partners Mochida Pharmaceutical Co.,
Ltd. (Mochida) and Mitsubishi Tanabe Pharma Corporation (MTPC) have launched
Lexapro(®) 10mg (escitalopram) in Japan, for which Mochida obtained the
marketing approval following the NHI (National Health Insurance) Drug Price
listing.
"It is a milestone in our global expansion strategy that Lexapro(®) is now
available in Japan following a fast regulatory process," says Lundbeck Senior
Vice President Ole Chrintz, International Markets. He continues: "We are pleased
that Lexapro(®) will now also contribute to improving quality of life for
patients in Japan diagnosed with depression."
Lexapro(®) has been very well-received by the patients and doctors for the
treatment of depression in many countries, and is currently the most prescribed
branded anti-depressant in the World.
Mochida and MTPC estimate sales of Lexapro(®) amounting to JPY 3 billion (DKK
~0.2 billion) for the first year following the launch and JPY 33.8 billion (DKK
~2.3 billion) in its peak year 6 years later.
For reference:
Brand Name: Lexapro(®) 10mg
Generic name: Escitalopram oxalate
Ingredients and Contents: 12.77mg escitalopram oxalate per tablet (10mg
escitalopram per tablet)
Indication: Depression and depressive symptoms
Dosage and Administration: Usually, to adults, 10mg of escitalopram is orally
administered once daily after meal in the evening. The dosage may be adjusted
according to the patient's age and symptoms; however, the daily dose should not
be increased over 20mg.
Package: 28,100,140,500 tablets (PTP), 500 tablets (Bottle)
NHI Drug Price: JPY 212.00 per tablet
Date of Approval: April 22, 2011
FIDDAMAN & CCHR / Scientology waste time as Antidepressants show signs of countering Alzheimer’s ?
Antidepressants show signs of countering Alzheimer’s
Mice and human data link treatment to fewer plaques in the brainBy Laura Sanders
Widely used antidepressants may reduce the ominous brain plaques associated with Alzheimer’s disease, a new study in mice and humans finds.
Brain scans of people who have taken antidepressants reveal fewer clumps of the protein amyloid-beta, a target of Alzheimer’s prevention strategies, when compared with people who have not taken the drugs.
Many in the field voiced caution about the results. But if borne out by further study, the findings may point to a new, relatively safe way to treat and prevent Alzheimer’s disease, which is the sixth leading cause of death in the United States.
“I think this is a wonderful piece of news, and I think there’s going to be a lot of excitement about this,” says internist Michael Weiner, who leads the Alzheimer’s Disease Neuroimaging Initiative at the Veterans Affairs Medical Center campus of the University of California, San Francisco. “It points the way towards a possible approach to treating Alzheimer’s disease that people have not been talking about very much.”
In the study, mice genetically engineered to overproduce amyloid-beta, or A-beta, were given one of three selective serotonin reuptake inhibitors, a class of antidepressants that boost circulating levels of the chemical messenger serotonin in the brain. After a single dose of the antidepressants, A-beta levels dropped in the fluid that surrounds mouse brain cells, researchers report online the week of August 22 in the Proceedings of the National Academy of Sciences. A full day after receiving the drug, the mice’s A-beta levels fell by nearly a quarter.
Long-term, chronic administration of the drug had a larger effect. Engineered mice that took the SSRI citalopram for four months had about half the A-beta plaques in their brains as mice that hadn’t had the drug. This reduction seems to happen through a protein called ERK, which serves as the middleman between brain cells’ serotonin-sensing proteins and A-beta production.
Figuring out the details of this process may open the door for developing new ways to prevent A-beta buildup, says study coauthor John Cirrito of the Washington University School of Medicine in St. Louis.
To see if a similar effect might be happening in people, the scientists scanned the brains of 186 cognitively normal elderly people and looked for signs of A-beta plaques. The team used a compound called PIB that binds to big clumps of A-beta in the brain and glows on a PET scan.
Of these participants, 52 reported that they had taken an antidepressant in the last five years. These people, researchers found, had about half the A-beta load in their brains as the people who hadn’t taken an antidepressant. What’s more, the length of time the participants took the drugs correlated with the density of A-beta plaques in the brain — the longer the antidepressant dose, the less plaque.
“We think there are influences going in two opposite directions,” says study coauthor and psychiatrist Yvette Sheline, also of Washington University. “We think depression pushes you toward dementia, but antidepressant treatment pushes you toward protection.”
Finding similar results in mice and humans lends the study credibility, Weiner says. “When you have animal data and human data coming together, then you start to get really excited,” he says.
Still, Weiner and others caution that it would be premature to conclude that antidepressants protect against A-beta buildup or that fewer plaques necessarily translate into less disease.
The study uncovered an association — not a clear-cut cause and effect, Weiner notes. “We cannot say with certainty that the reason why people who took the SSRIs have lower cortical amyloid is due to the fact that they took SSRIs,” he says.
And molecular neuroscientist Heather Snyder of the Alzheimer’s Association in Chicago points out that even if antidepressants are shown to reduce A-beta, scientists still don’t know how A-beta levels affect the brain. “We don’t really know what modulating amyloid will do to cognition,” she says. “And we don’t know if we need to reduce it by 10 percent or 20 percent, or if it needs to be completely reversed.”
Another confounding factor is that A-beta can take several forms in the brain, from small molecules to large, sticky clumps, and some forms may be more dangerous than others. Interpreting the A-beta clumps that PIB detects in human brain scans remains challenging.
“We’re being very cautious,” Cirrito says. “There are a lot of people on these drugs and we don’t want to get anybody overly excited without reason.” He and his colleagues plan to test whether acute doses of SSRIs change A-beta levels in the cerebrospinal fluid of healthy human subjects.
Even if the new findings are replicated in larger studies, a major question about Alzheimer’s and antidepressants remains, Sheline says. “The real question is — which this paper sheds no light on — does that mean that long-term, they [SSRI-treated people] will have less of a risk of dementia? And that’s exactly the big study that needs to be done.”
Bob Fiddaman Scientology - most popular search term
VISITOR ANALYSIS
Referrer http://www.google.com.au/url?sa=t&source=web&cd=1&ved=0CCoQFjAA&url=http%3A%2F%2Fbobfiddaman.blogspot.com%2F2011%2F02%2Fbob-fiddaman-scientologist-award-night.html&rct=j&q=bob%20fiddaman%20scientology&ei=ZrNPTp-xCOPKiAK7kfmPAQ&usg=AFQjCNGFLjRs5FmlAG0MFEYfwtcXaaVMsA
Search Engine Phrase bob fiddaman scientology
Search Engine Name Google
Search Engine Host www.google.com.au
Host Name 125-168-6-230.wbroadband.net.au
IP Address 125.168.6.230 [Label IP Address]
Country Australia
Region Victoria
ISP Wcgnet, Wholesale Communications Group
Returning Visits
Visit Length Multiple visits spread over more than one day
Pat McGorry's response - to FIDDAMAN misrepresentations
Given that FIDDAMAN stretches things a bit - we give you an EXCLUSIVE peek at the proposed DELOREAN 4 door DMC24
Just like Bob Fiddaman it was a work of pure fantasy
Now back to the present
Response to The Sunday Age article of 21st August 2011
Submitted by Pat McGorry on 22 August 2011 - 6:45am
http://www.patmcgorry.com.au/blog/pmcgorry/response-sunday-age-article-21st-august-2011
For the second time in two weeks, a front page article in The Sunday Age by Jill Stark contains selective and inaccurate information, unsubstantiated claims and innuendo to falsely imply unethical behaviour on my part and to mischaracterize the nature of youth mental health reforms recently supported by the Australian Government. Both articles are likely to result in reputational damage to myself and significant public confusion about mental health reform that risks undermining the confidence of young people and their families to seek help in the new youth mental health services currently being established around Australia.
I have previously addressed the inaccuracies and misrepresentations in The Sunday Age article of 7th August and will now deal with the most recent set of inaccuracies and misrepresentations.
The article is entirely based on misleadingly linking two entirely separate events. These events are:
1.the decision of Orygen Youth Health Research Centre (for which I am Executive Director) not to proceed with an already ethically approved trial of the medication Quetiapine in a population of 15-40 year olds assessed as being of high risk of developing a psychotic disorder within the next 12 months
2.the receipt of correspondence by the research ethics committee of Melbourne Health querying its decision last year to approve the trial.
By linking these two unrelated events, the article misleadingly conveys the impression that Orygen Youth Health Research Centre and I withdrew the trial arising from fears that our work might be found to be unethical if the committee were for some reason to change its original decision.
Prior to the article being filed, The Sunday Age was provided with a detailed chronology of events that demonstrated no linkage between the correspondence to the research committee and our decision not to proceed with the trial. The unrelated nature of the two events was corroborated by one of the proposed lead researchers. Despite this information being furnished to the paper prior to the article being completed, The Sunday Age made a news judgement to dedicate its front page to a story that was entirely premised on a linkage between two events that the paper had no reason to believe were connected.
A number of other aspects of the article are more likely to mislead than to inform. The sub-headline on the print edition of The Sunday Age wrongly described the trial as a “child study” even though the intended population was 15-40 year olds. This age group is correctly termed late adolescence and early to middle adulthood. Similarly, a number of important and independently verifiable facts were reported merely in the form of uncorroborated assertions by me. These verifiable facts include that the research trial had already received ethics approval by Melbourne Health and that the decision not to proceed with the trial occurred before the appeal to the ethics committee had been made.
A key goal of youth mental health models headspace and EPPIC is to address the over medication of people with mental ill-health in our overstretched and under-resourced mental health system. Yet the article fans fears that the opposite may be the case. The article reports completely baseless and unsubstantiated fears that the clinical guidelines of Early Psychosis Prevention and Intervention Centres (EPPICs) will be changed to recommend the use of anti-psychotic medication to people without a diagnosed psychotic disorder. More confusion is caused when the article incorrectly defines early intervention only in terms of preventing psychotic illnesses as opposed to treating diagnosed psychotic disorders. As a result, and in conjunction with the wider context of the article, young people and their families may feel confused and uncertain about whether to seek help at an EPPIC service for illnesses with devastating impacts. The potential for harm to seriously ill young people is obvious and should have been foreseen by the newspaper.
Additional Note:
Orygen Youth Health Research Centre is principally funded by public and philanthropic funds. Less than 5% of our budget is from pharmaceutical companies, who neither design the research we conduct nor restrict our right to publish the results of our research. Our focus is to ensure young people with mental ill-health have a holistic range of supports made available to them, in particular extensive psycho-social interventions.
Sunday, 21 August 2011
Saturday, 20 August 2011
Bob Fiddaman + Scientology - major interest from AUSTRALIA in FIDDAMAN scammer
Search Engine Phrase bob fiddaman scientology
Search Engine Name Google
Search Engine Host www.google.com.au
Host Name 125-168-6-230.wbroadband.net.au
IP Address 125.168.6.230 [Label IP Address]
Country Australia
Region Victoria
City Melbourne
ISP Wcgnet, Wholesale Communications Group
Returning Visits 0
Visit Length 8 hours 11 mins 38 secs
EXCLUSIVE - FIDDAMAN new book - How to Bully Online Bob Fiddaman Style
* Get updated on Bob's hit-and-run twitter tactics
* Learn how to be a petulant child in five minutes or less
*Which adult diapers to use when you can't pull yourself away from the computer and are forced to sit in your own waste for hours
MHRA Yellow Card report Ubertan here - http://www.yellowcard.gov.uk/
Consumers warned of the potential dangers of tanning nasal spray
Fake tanning products have become increasingly popular as they should be safer than spending hours in the sun to achieve the ideal tan.owever, experts here at the MHRA have warned that a sunless tanning treatment, marketed as Ubertan, is in fact an unlicensed medicine. This means it contains substances that have not been properly tested so there is no evidence of safety, quality or that it works, and its potential side effects are unknown.
This treatment is being advertised and sold illegally in gyms and beauty salons, as well as online, and is used in the form of a nasal spray.
MHRA Head of the Medicines Borderline Section, David Carter, said, “Putting your health on the line just in order to get a tan is just really not worth the risk.”
He warns those who have purchased this product to not use it again and to throw it in the bin. He also advises those with concerns to speak to their GP or healthcare advisor.
The Yellow Card scheme is vital in helping us monitor the safety of medicines and identifying side effects. It we decide that the risk associated with the medicine outweighs the benefit then we take action.
Fake tanning products have become increasingly popular as they should be safer than spending hours in the sun to achieve the ideal tan.owever, experts here at the MHRA have warned that a sunless tanning treatment, marketed as Ubertan, is in fact an unlicensed medicine. This means it contains substances that have not been properly tested so there is no evidence of safety, quality or that it works, and its potential side effects are unknown.
This treatment is being advertised and sold illegally in gyms and beauty salons, as well as online, and is used in the form of a nasal spray.
One version of Ubertan contains melanotan II and another claims to contain an extract from the Indian plant 'coleus forskohlii'. There are no licensed or registered medicines in the UK that contain melanotan or this herbal extract.
MHRA Head of the Medicines Borderline Section, David Carter, said, “Putting your health on the line just in order to get a tan is just really not worth the risk.”
He warns those who have purchased this product to not use it again and to throw it in the bin. He also advises those with concerns to speak to their GP or healthcare advisor.
If you have a problem with Ubertan, or any other medicinal product, you can report it via our Yellow Card scheme – http://www.blogger.com/goog_1291191820
The Yellow Card scheme is vital in helping us monitor the safety of medicines and identifying side effects. It we decide that the risk associated with the medicine outweighs the benefit then we take action.
Retailers selling an unlicensed tanning nasal spray - to be jailed by MHRA
Retailers selling an unlicensed tanning nasal spray which has potentially serious side effects could face jail following legal action by a government watchdog.
Action by the Medicines and Healthcare products Regulatory Agency (MHRA) means the owners of ubertan.com and two other sellers could face a maximum two-year prison sentence.
Manufacturing products containing the compound melanotan II is not illegal, but selling them and advertising them is. Nine different retailers are under investigation.
Read more: http://www.dailymail.co.uk/health/article-2028201/Owners-fake-tan-nasal-spray-face-years-prison.html#ixzz1VZDV3k5q
Thursday, 18 August 2011
#JanEastgate hearing done in chambers. #stupidscientology #anonymous
#JanEastgate hearing done in chambers. Will post info after 2pm EST until then we can't get info. #stupidscientology #anonymous
3 minutes ago
Wednesday, 17 August 2011
Glaxosmithkline - checking out the SEROXAT FRAUDSTERS
Glaxosmithkline (198.28.69.5) GSK [Edit Label]
United Kingdom, 19 returning visits
Date Time Type WebPage
17th August 2011 11:55:00 Page View www.google.co.uk/search?q=seroxat victims&ie=utf-8&oe=utf-8&aq=t&rls=org.mozilla:en-GB:official&client=firefox-a&safe=images
bobfiddaman.blogspot.com
Janice Simmons
Derek Scott
Sarah Venn
Atos doctors could be struck off - report dishonest doctors to GMC
Atos doctors could be struck off
Twelve medics at the disability assessment centre are under investigation by the GMC over allegations of improper conduct
Atos practices concerning welfare and disability assessment have come under intense criticism. Photograph: Dan Kitwood/Getty Images
Twelve doctors employed by the firm that is paid £100m a year to assess people claiming disability benefit are under investigation by the General Medical Council over allegations of improper conduct. The doctors, who work for Atos Healthcare, a French-owned company recently criticised by MPs for its practices, face being struck off if they are found not to have put the care of patients first.
The Observer has found that seven of the doctors have been under investigation for more than seven months. The other five were placed under investigation this year following complaints about their conduct.
It is understood that the majority of allegations concern the treatment of vulnerable people when the government's controversial "work capability assessments" were carried out, but the GMC refused to comment on individual cases. The development will add to fears over the pace and radical agenda behind the government's welfare-to-work policy, which led to protests in Westminster in May by thousands of disabled people. It will also raise concerns about ministers' commitment to Atos Healthcare, which was recently granted a three-year extension on its contract.
The government has repeatedly publicised figures showing that the "vast majority" of claimants for employment support allowance (ESA), which has replaced incapacity benefit, are fit for work. But four out of 10 of those who appealed the decision by Atos - whose parent company is run by a former French finance minister, Thierry Breton - to deny them benefits are successful on appeal, a process that costs the taxpayer £50m a year.
Last month Atos, whose staff assess around 11,000 benefit claimants a week, was savaged by the cross-party work and pensions select committee after it found that many people had "not received the level of service from Atos which they can reasonably expect".
MPs further claimed that a combination of the company's conduct and the test itself had prompted "fear and anxiety among vulnerable people".
One GP who attended an Atos recruitment fair told the Observer she feared doctors could become "agents of the state" who were deprofessionalised by involvement in a system that did not make patient care its first concern.
Campaigners for the disabled seized upon the development, claiming the government needed to go back to the drawing board. Richard Hawkes, chief executive of the charity Scope, said: "If the government wants to get disabled people off benefits and into work then it needs to get its assessment right. The test should be the first step on the road to employment. But disabled people's confidence in the work capability assessment is extremely low â and today's news will send it to rock bottom.
"The test is massively flawed. Now it appears that it is being carried out by a large number of doctors who are under serious investigation."
Neil Bateman, a solicitor who handles ESA appeals, said on two occasions his clients had been successful because, among other reasons, the doctor assessing them had qualified in Romania and registered with the GMC but had not been licensed to practise in Britain.
Citizens Advice told the Observer it was compiling a dossier showing the problems being faced by those assessed by Atos staff, who can be nurses or physiotherapists in cases where there are no potential neurological disorders. It said it regularly found inaccuracies in many of the medical reports featured in ESA appeal papers that could affect people's chances of receiving benefits. It also found a lack of consideration for those being assessed.
A spokesman said a barrister who was unable to practise because of cancer and lymphoma had described the assessment as being like an "interrogation" led by a computer. The assessor moved the client's legs, which caused her great pain, even though the client had warned that this would happen. In another case a claimant with learning difficulties who went for an assessment was found fit for work because he had found his way to the assessment centre on his own.
When asked about this by Citizens Advice, he reluctantly explained that he had got up very early, taken the bus to the town centre, and then kept asking passersby for directions. He couldn't follow their instructions, so he would show the letter, walk in the direction they pointed, then ask again until he arrived.
Two doctors employed by Atos have already been taken by the GMC to an independent panel for adjudication on their fitness to practise. Dr Alexandros Mallios, who it was claimed had not carried out a proper examination of his patient during an assessment, was cleared by the panel last October. Dr Usen Samuel Ikidde, who qualified in Nigeria, was given a formal warning in January, to lay on his records for five years, after he was found to have worked for Atos while on sick leave from an accident and emergency department.
An Atos spokesman said: "Atos Healthcare is committed to providing a high-quality, professional service and requires these standards of all its employees. While we cannot comment on individual cases, any complaint made about an employee is taken extremely seriously.
"In addition to our own rigorous internal investigations we will co-operate with any external investigation to ensure all facts are properly established and the appropriate action taken."
The Labour government introduced work capability assessments in 2008 when it replaced incapacity benefit and income support for new claimants with employment and support allowance. The government has accelerated the changes and started retesting all 1.5 million incapacity benefit claimants to see whether they are eligible for the new benefit.
A GMC spokesman said: "We can and do take action to remove or restrict a doctor's right to practise if there have been serious failures to meet our standards."
Twelve medics at the disability assessment centre are under investigation by the GMC over allegations of improper conduct
Atos practices concerning welfare and disability assessment have come under intense criticism. Photograph: Dan Kitwood/Getty Images
Twelve doctors employed by the firm that is paid £100m a year to assess people claiming disability benefit are under investigation by the General Medical Council over allegations of improper conduct. The doctors, who work for Atos Healthcare, a French-owned company recently criticised by MPs for its practices, face being struck off if they are found not to have put the care of patients first.
The Observer has found that seven of the doctors have been under investigation for more than seven months. The other five were placed under investigation this year following complaints about their conduct.
It is understood that the majority of allegations concern the treatment of vulnerable people when the government's controversial "work capability assessments" were carried out, but the GMC refused to comment on individual cases. The development will add to fears over the pace and radical agenda behind the government's welfare-to-work policy, which led to protests in Westminster in May by thousands of disabled people. It will also raise concerns about ministers' commitment to Atos Healthcare, which was recently granted a three-year extension on its contract.
The government has repeatedly publicised figures showing that the "vast majority" of claimants for employment support allowance (ESA), which has replaced incapacity benefit, are fit for work. But four out of 10 of those who appealed the decision by Atos - whose parent company is run by a former French finance minister, Thierry Breton - to deny them benefits are successful on appeal, a process that costs the taxpayer £50m a year.
Last month Atos, whose staff assess around 11,000 benefit claimants a week, was savaged by the cross-party work and pensions select committee after it found that many people had "not received the level of service from Atos which they can reasonably expect".
MPs further claimed that a combination of the company's conduct and the test itself had prompted "fear and anxiety among vulnerable people".
One GP who attended an Atos recruitment fair told the Observer she feared doctors could become "agents of the state" who were deprofessionalised by involvement in a system that did not make patient care its first concern.
Campaigners for the disabled seized upon the development, claiming the government needed to go back to the drawing board. Richard Hawkes, chief executive of the charity Scope, said: "If the government wants to get disabled people off benefits and into work then it needs to get its assessment right. The test should be the first step on the road to employment. But disabled people's confidence in the work capability assessment is extremely low â and today's news will send it to rock bottom.
"The test is massively flawed. Now it appears that it is being carried out by a large number of doctors who are under serious investigation."
Neil Bateman, a solicitor who handles ESA appeals, said on two occasions his clients had been successful because, among other reasons, the doctor assessing them had qualified in Romania and registered with the GMC but had not been licensed to practise in Britain.
Citizens Advice told the Observer it was compiling a dossier showing the problems being faced by those assessed by Atos staff, who can be nurses or physiotherapists in cases where there are no potential neurological disorders. It said it regularly found inaccuracies in many of the medical reports featured in ESA appeal papers that could affect people's chances of receiving benefits. It also found a lack of consideration for those being assessed.
A spokesman said a barrister who was unable to practise because of cancer and lymphoma had described the assessment as being like an "interrogation" led by a computer. The assessor moved the client's legs, which caused her great pain, even though the client had warned that this would happen. In another case a claimant with learning difficulties who went for an assessment was found fit for work because he had found his way to the assessment centre on his own.
When asked about this by Citizens Advice, he reluctantly explained that he had got up very early, taken the bus to the town centre, and then kept asking passersby for directions. He couldn't follow their instructions, so he would show the letter, walk in the direction they pointed, then ask again until he arrived.
Two doctors employed by Atos have already been taken by the GMC to an independent panel for adjudication on their fitness to practise. Dr Alexandros Mallios, who it was claimed had not carried out a proper examination of his patient during an assessment, was cleared by the panel last October. Dr Usen Samuel Ikidde, who qualified in Nigeria, was given a formal warning in January, to lay on his records for five years, after he was found to have worked for Atos while on sick leave from an accident and emergency department.
An Atos spokesman said: "Atos Healthcare is committed to providing a high-quality, professional service and requires these standards of all its employees. While we cannot comment on individual cases, any complaint made about an employee is taken extremely seriously.
"In addition to our own rigorous internal investigations we will co-operate with any external investigation to ensure all facts are properly established and the appropriate action taken."
The Labour government introduced work capability assessments in 2008 when it replaced incapacity benefit and income support for new claimants with employment and support allowance. The government has accelerated the changes and started retesting all 1.5 million incapacity benefit claimants to see whether they are eligible for the new benefit.
A GMC spokesman said: "We can and do take action to remove or restrict a doctor's right to practise if there have been serious failures to meet our standards."
Subscribe to:
Posts (Atom)